Dainippon Sumitomo in option deal for Boston's stem cellness inhibitor
This article was originally published in Scrip
Dainippon Sumitomo Pharma (DSP) has acquired an option to Boston Biomedical's BBI608, a novel oral small molecule oncology drug targeting stem cell-like cancer cells. The deal is worth $15 million on signing to the privately held US firm and DSP will also support clinical development activities.
You may also be interested in...
Given its ever-growing role as a critical component of the global biopharma industry, you can’t afford not to be up to speed on Asia. This biweekly selection of insights from our experienced on-the-ground team will help.
Plus deals involving LegoChem/Pyxix, Biohaven/Sosei Heptares, Kyowa Kirin/Helsinn, Dr. Reddy’s/Glenmark, Eisai/Wren, KoBioLabs/Kolmar Korea, Y-Biologics/Pierre Fabre, Generex/Chinese consortium.
Join us for a brief audio tour around the past week's major global biopharma industry developments, in this podcast version of Scrip's Five Must-Know Things.